Premium
Biologics in the Treatment of Chronic Pain: A New Era of Therapy?
Author(s) -
Bannwarth B,
Kostine M
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.20
Subject(s) - tolerability , medicine , chronic pain , pain relief , intensive care medicine , nerve growth factor , physical therapy , anesthesia , adverse effect , pharmacology , receptor
Existing analgesics fail to provide adequate pain relief in a significant proportion of patients complaining of chronic pain. Furthermore, their use is limited by tolerability and safety concerns. Thus, there is a huge unmet need for effective and safe innovative painkillers. Considering the major role of nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, the issue is whether anti‐NGF biologics under development might offer such an opportunity.